. . "3.1 hours"@en . . . . . . . "# Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11219478 # Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10651391 # Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11764864 # Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11190346"@en . . "Enterococcus faecalis"@en . . . . . . . . "Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome. Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation it, enhancing the binding of quinupristin by a factor of about 100. In addition, it inhibits peptidyl transferase. Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released."@en . . . . . . . . . "Enteric bacteria and other eubacteria"@en . . "Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone."@en . . "approved"@en . "120138-50-3"@en . . . "Moderate."@en . . . . . "Quinupristin"@en . . . "For the treatment of bacterial infections (usually in combination with dalfopristin)."@en . . . . . . . " "@en .